Fly News Breaks for January 27, 2020
Jan 27, 2020 | 20:25 EDT
Oppenheimer analyst Suraj Kalia initiated coverage of Inspire Medical with an Underperform rating and $50 price target. The analyst cites his due diligence and field checks, suggesting that while its commercialized hypoglossal nerve stimulation in obstructive sleep apnea patients has a role in the treatment market, it is not a "cure all", while the total addressable market is also not particularly large. Kalia further notes that the challenges in adopting this therapy are "complicated" and are not "properly appreciated" by the Street.
News For INSP From the Last 2 Days
There are no results for your query INSP